跳至主要内容
临床试验/NL-OMON53671
NL-OMON53671尚未招募4 期

A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis - M22-000

AbbVie B.V.0 个研究点目标入组 14 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方
AbbVie B.V.
入组人数
14

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • - Male or female subjects >= 18 and < 65 years of age at the screening visit
  • - Chronic AD with onset of symptoms at least 3 years prior to Baseline and
  • subject meets Hanifin and Rajka criteria - Candidate for systemic treatment

排除标准

  • - Prior exposure to any JAK inhibitor
  • - Unable or unwilling to discontinue current AD treatments prior to the study
  • - Requirement of prohibited medications during the study treatment
  • - Female subject who is pregnant, breastfeeding, or considering pregnancy
  • during the study

研究者

发起方
AbbVie B.V.

相似试验

进行中(未招募)
1 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic DermatitisDermatitis atopicMedDRA version: 20.0Level: PTClassification code: 10012438Term: Dermatitis atopic Class: 100000004858
CTIS2023-504869-23-00AbbVie Deutschland GmbH & Co. KG438
进行中(未招募)
1 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjectswith Moderate to Severe Atopic DermatitisModerate to Severe Atopic DermatitisMedDRA version: 20.0Level: PTClassification code 10012438Term: Dermatitis atopicSystem Organ Class: 10040785 - Skin and subcutaneous tissue disorders
EUCTR2022-000434-42-SKAbbVie Deutschland GmbH & Co. KG454
进行中(未招募)
1 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis
EUCTR2022-000434-42-NLAbbVie Deutschland GmbH & Co. KG454
招募中
4 期
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic DermatitisAtopic Dermatitis
JPRN-jRCT2011230021Yamazaki Hayato454
进行中(未招募)
不适用
A Phase 3, Randomized, Single-Blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical HaemostasisIntraoperative Surgical Hemostasis (Spinal Surgery, Vascular Surgery, Hepatic resection, Soft tissue dissection)MedDRA version: 14.1Level: LLTClassification code 10053001Term: Surgical haemostasisSystem Organ Class: 100000004865
EUCTR2011-006174-47-NLProFibrix Inc.672